Payment overview · 2025
General Payments
$1,299.17
66 reported records · 20 companies
Healthcare provider profile · identity verified
Vivian E Lan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EMERSON, NJ · NPI 1619912284
Verified facts
What the public records show
CMS Open Payments records show Vivian E Lan, MD received $1,299.17 in general payments during 2025 across 66 reported records.
Novo Nordisk Inc accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $221.95 | 17.1% | 7 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $172.06 | 13.2% | 10 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $169.29 | 13.0% | 9 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $92.61 | 7.1% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $82.50 | 6.3% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.65 | 5.8% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $72.00 | 5.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.70 | 4.1% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.24 | 3.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.47 | 3.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.29 | 3.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.00 | 2.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.77 | 2.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.50 | 2.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.99 | 2.2% | 1 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $24.35 | 1.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.99 | 1.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.48 | 1.4% | 1 | 2025 |
| Biocon Biologics Inc | Unresolved — no canonical attribution shown | $18.44 | 1.4% | 1 | 2025 |
| Intercept Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.89 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,299.17 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $172.06 | 10 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $169.29 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $142.39 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $92.61 | 5 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $82.50 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $74.65 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $72.00 | 4 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $50.24 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $39.47 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.77 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.77 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.63 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.99 | 1 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| Yesintek Normalized: yesintek |
Biological | Biocon Biologics Inc | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| OCALIVA Normalized: ocaliva |
Drug | Intercept Pharmaceuticals, Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
105 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 403 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 402 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 112 |
| Alprazolam | Alprazolam | 299 | 93 |
| Simvastatin | Simvastatin | 253 | 78 |
| Metformin Hcl | Metformin Hcl | 246 | 83 |
| Losartan Potassium | Losartan Potassium | 239 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 58 |
| Lisinopril | Lisinopril | 157 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 150 | 44 |
| Meloxicam | Meloxicam | 146 | 66 |
| Valsartan | Valsartan | 135 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 34 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 106 | 33 |
| Synthroid | Levothyroxine Sodium | 105 | 29 |
| Sertraline Hcl | Sertraline Hcl | 89 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 30 |
| Atenolol | Atenolol | 66 | 23 |
| Alendronate Sodium | Alendronate Sodium | 61 | 19 |
| Omeprazole | Omeprazole | 61 | 25 |
| Azithromycin | Azithromycin | 54 | 52 |
| Eliquis | Apixaban | 54 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 26 |
| Furosemide | Furosemide | 51 | 20 |
| Allopurinol | Allopurinol | 47 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 14 |
| Bupropion Xl | Bupropion Hcl | 38 | 13 |
| Lorazepam | Lorazepam | 38 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 16 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 11 |
| Famotidine | Famotidine | 29 | 12 |
| Azelastine Hcl | Azelastine Hcl | 28 | 11 |
| Gabapentin | Gabapentin | 26 | 13 |
| Carvedilol | Carvedilol | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | 11 |
| Montelukast Sodium | Montelukast Sodium | 23 | 11 |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 22 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | 11 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 13 |
| Glipizide Er | Glipizide | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,299.17 · 66 records | Novo Nordisk Inc | Bimzelx, CREON, Cologuard Collection Kit, DUPIXENT, ELIQUIS, ENTYVIO, EVENITY, IBSRELA, LINZESS, MOUNJARO, NURTEC ODT, OCALIVA, OMVOH, Ozempic, RECORLEV, REZDIFFRA, Rybelsus, SHINGRIX, Sucraid, TREMFYA, Tymlos, VOQUEZNA, VRAYLAR, Veozah, Wegovy, Yesintek | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error